Cemiplimab Clinical Trials

67 actively recruiting trials across 29 locations

▼ -3 trials since June 2026

Also known as: 1801342-60-8, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal REGN2810 Heavy Chain), Cemiplimab RWLC, Cemiplimab-rwlc, Dimer +17 more

Pipeline

Phase 1: 14Phase 2: 33Phase 3: 5Phase 1/2: 11Phase 2/3: 1

Top Sponsors

Regeneron Pharmaceuticals14
National Cancer Institute (NCI)5
M.D. Anderson Cancer Center5
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
Mayo Clinic3

Indications

Cancer67
Lung Cancer20
Non Small Cell Lung Cancer8
Solid Tumor4
Clear Cell Renal Cell Carcinoma (ccRCC)3

Other12 trials

A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

Phase 3

A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC

Phase 3

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

Phase 1

Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer

Phase 2

An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

Cemiplimab as Maintenance Treatment for Advanced Adrenocortical Cancer

Phase 2

ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer

Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

Phase 2

Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

Phase 2

PALACE: Cemiplimab Trial According to ctDNA Levels

Phase 2

Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%

Phase 2

New York, New York5 trials

Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

Columbia University Irving Medical Center

Phase 2

Gemcitabine, Cisplatin, Nab-paclitaxel (GAP) and Cemiplimab for Locally Advanced Biliary Tract Cancer (BTC)

Columbia University Irving Medical Center

Phase 2

Gemcitabine/Cisplatin Plus Cemiplimab With or Without Fianlimab in Localized Muscle-invasive Bladder Cancer (NeoSTOP-IT)

Columbia University Irving Medical Center/ New York Presbyterian Hospital

Phase 2

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

Icahn School of Medicine at Mount Sinai

Phase 1/2

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Weill Cornell Medicine

Phase 2

Los Angeles, California4 trials

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.

California Research Institute

Phase 1

A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body

USC Norris Comprehensive Cancer Center

Phase 1/2

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

University of California Los Angeles

Phase 2

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma

The Angeles Clinic and Research Institute

Phase 2

Houston, Texas4 trials

A Ph Ib Study of REGN5678 Plus Cemiplimab in Patients With mCRPC

The University of Texas M. D. Anderson Cancer Center

Phase 1

Cemiplimab and Cetuximab Prior Salvage Surgery in Patients With Recurrent Oral Cavity and HPV-negative Oropharyngeal Squamous Cell Carcinoma

MD Anderson Cancer Center

Phase 2

Phase II Biomarker Study of BND-22 in Combination With Cemiplimab in Solid Tumors

Md Anderson Cancer Center

Phase 2

Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies

MD Anderson Cancer Center

Phase 2

Birmingham, Alabama3 trials

I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

University of Alabama at Birmingham

Phase 2

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

University of Alabama_6th Ave

Phase 1/2

Duarte, California3 trials

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

Site-113

Phase 1/2

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

City of Hope Comprehensive Cancer Center

Phase 1/2

Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer

City of Hope Medical Center

Phase 2

Atlanta, Georgia3 trials

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer

Emory University/Winship Cancer Institute

Phase 1

Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy

Emory University Hospital Midtown

Phase 2

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Emory University Hospital Midtown

Phase 1/2

Baltimore, Maryland3 trials

Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer

Johns Hopkins SKCCC

Phase 2

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

Johns Hopkins University

Phase 2

Boston, Massachusetts3 trials

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Massachusetts General Hospital Cancer Center

Phase 1/2

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

Massachusetts General Hospital

Phase 1

XL092 and Cemiplimab in BRAF WT Thyroid Cancer

Dana Farber/Harvard Cancer Center

Phase 1

Phoenix, Arizona2 trials

Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets

St. Joseph's Hospital and Medical Center

Phase 3

Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma

Medical Dermatology Specialists - Phoenix

Phase 3

Scottsdale, Arizona2 trials

A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma

Mayo Clinic in Arizona

Phase 1

Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma

Mayo Clinic in Arizona

Phase 1

Irvine, California2 trials

Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 2

La Jolla, California2 trials

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

UC San Diego Moores Cancer Center

Phase 2

Basking Ridge, New Jersey2 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1

A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activites)

Phase 2

Nashville, Tennessee2 trials

A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

Vanderbilt-Ingram Cancer Center

Phase 2

Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Daphne, Alabama1 trial

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis

Phase 2/3

Chandler, Arizona1 trial

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Ironwood Cancer & Research Centers

Phase 3

Gilbert, Arizona1 trial

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Banner MD Anderson Cancer Center

Phase 1/2

Tucson, Arizona1 trial

Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Banner University Medical Center - Tucson

Phase 2

Newport Beach, California1 trial

A Phase 1 Study of BHV-1530 in Advanced Solid Tumors

Site-111

Phase 1

Orange, California1 trial

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

University of California Irvine

Phase 2

Palo Alto, California1 trial

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer

Stanford University Medical Center - Blake Wilbur Drive

Phase 1/2

Gainesville, Florida1 trial

A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (EMPIRE)

University of Florida

Phase 2

Iowa City, Iowa1 trial

5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors

University of Iowa Health Care

Phase 1

Lexington, Kentucky1 trial

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1

Bethesda, Maryland1 trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

National Cancer Institute

Phase 1

Rochester, Minnesota1 trial

Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer

Mayo Clinic in Rochester

Phase 2

The Bronx, New York1 trial

Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer

Montefiore Einstein Comprehensive Cancer Center (MECCC)

Phase 2

Columbus, Ohio1 trial

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2

Austin, Texas1 trial

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents

NEXT Austin

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.